series-c-plus
Stage
1
Investors
About
Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its lead product candidate is atacicept, a fusion protein that blocks B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), targeting autoimmune diseases such as IgA nephropathy and lupus nephritis.
Explore Vera Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.